This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

American Pharmaceutical Merges With Holder

American Pharmaceutical Partners (APPX) plans to merge with its parent company, privately held American BioScience, uniting two outfits founded by Patrick Soon-Shiong and bringing their controversial management structure under the same roof.

Through an all-stock transaction, the companies will merge and become known as Abraxis BioScience. American BioScience currently owns about 64.4% of American Pharmaceutical. The companies expect to close the deal in the first half of 2006.

"We believe this merger is a unique opportunity to combine the strengths of a development-stage biotechnology company with those of a growing and profitable injectable pharmaceutical business to create a fully integrated, global biopharmaceutical leader," said Soon-Shiong, the executive chairman of American Pharmaceutical and the chairman and CEO of American BioScience.

Shareholders of American Pharmaceutical were miffed upon learning of the deal, and they sent the stock down $7.66, or 16.1%, to $39.95.

On the basis of American Pharmaceutical's closing stock price Nov. 25, the combined company would have a market value of about $7.5 billion. Combined revenue would exceed $500 million.

American Pharmaceutical will issue about 86 million shares to American BioScience stockholders, raising American BioScience's stake in the combined company to roughly 83.5%.

Soon-Shiong has now assumed the duties of chairman and chief executive of American Pharmaceutical, replacing Al Heller, who resigned as the company's CEO and as a member of the board. Soon-Shiong who will be chairman and CEO of Abraxis BioScience once the merger is completed.

The centerpiece of the companies' merger is the breast cancer drug Abraxane, a branded product that was approved by the Food and Drug Administration earlier in the year. Other products the firm will own will include an injectables business focused on the oncology, critical care and anti-infective markets.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $117.34 -0.81%
FB $107.12 2.76%
GOOG $767.04 3.29%
TSLA $237.19 3.01%
YHOO $33.71 -0.30%


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs